PHILADELPHIA — Women who are diagnosed with peripartum cardiomyopathy (PPCM) during late pregnancy or within a month following delivery are more likely to experience restored cardiac function and improved outcomes compared to those who are diagnosed later in the postpartum period, according to a new study from Penn Medicine. The findings underscore the need for increased awareness and monitoring of heart failure symptoms, particularly among black women, who, on average, are diagnosed significantly later than white patients, researchers found.
Authors say the findings, published in Hypertension and presented at the American Heart Association’s 2019 Scientific Sessions, may explain the striking disparities in outcomes between white and black patients with PPCM. In a previous study, published in JAMA Cardiology, the team found black women were only about half as likely to return to normal levels of cardiac function and took twice as long to do so.
“Our findings demonstrate that important racial disparities exist not only in the outcomes of patients with PPCM, but in the timing of diagnosis and baseline level of cardiac function,” said the study’s lead author Jennifer Lewey, MD, MPH, director of the Women’s Cardiovascular Health Program and co-director of the Pregnancy and Heart Disease Program at Penn Medicine. “Cardiomyopathy is the leading cause of maternal mortality in the postpartum period, and while we recommend increased monitoring for peripartum cardiomyopathy in all patients, it’s particularly important in black women. Earlier diagnoses of PPCM may help to prevent the poor outcomes and expedite their recovery to normal cardiac function.”
PPCM, which affects at least one in 2,000 pregnancies in the United States, is a rare, potentially life-threatening form of heart failure in which the heart muscle becomes weak—often during the final month of pregnancy or in the first few months after delivery. Although the majority of patients, about 60 to 70 percent, experience a recovery to normal cardiac function, about 13 percent of patients experience severe, persistent cardiac dysfunction and can require a heart transplant or left ventricular assist device (LVAD), a mechanical pump that helps the left ventricle pump blood to the rest of the body.
Hypertensive disorders of pregnancy (HDP), such as gestational hypertension (high blood pressure noted in the latter part of pregnancy) and preeclampsia (a dangerous complication characterized by high blood pressure), are the strongest risk factors for PPCM. Previous studies have noted that patients with HDP and, ultimately, PPCM may fare better than those who do not develop HDP prior to PPCM. The studies suggest that if HDP contributes to the development of PPCM, the resolution of postpartum high blood pressure and restoration of normal blood vessel formation could accelerate one’s recovery to normal cardiac function. However, several studies have demonstrated that no such relationship exists.
To further examine how HDP and the timing of diagnosis impact patient outcomes, the Penn team conducted a retrospective study of 220 patients diagnosed with PPCM. Although women with HDP are diagnosed with PPCM earlier in the postpartum period, researchers found that women with HDP and PPCM experienced similar rates of left ventricular ejection fraction (LVEF) as those without HDP (68 percent and 63 percent, respectively). However, they found that patients who were diagnosed with PPCM more than a month after the delivery had significantly lower rates of cardiac recovery than those who were diagnosed earlier (54 percent vs. 70 percent). Patients who received an early diagnosis generally had higher baselines of cardiac function, likely contributing to the improved outcomes, authors suggest.
Additionally, researchers found that the majority of white patients with PPCM and HDP were diagnosed within a week of delivery. However, black patients with PPCM and HDP were most likely to be diagnosed between one and five months postpartum, with a small percentage diagnosed even beyond the five-month mark.
“While we are still investigating the factors—such as genetics and socioeconomic status—that lead to later diagnosis in this population, we hope our findings help to increase awareness of the need for proactive monitoring,” said the study’s senior author Zoltan Arany, MD, PhD, a professor of Cardiovascular Medicine at Penn.
Lewey will present her research at 1:30 pm ET on Saturday, November 16, in Zone 2 of the Science and Technology Hall at the Pennsylvania Convention Center in Philadelphia.
The work was supported, in part, by grants from the National Institutes of Health (NIH) (K12HD085848 and R01HL126797) and a NIH CTSA SPIRIT award. Additional Penn authors include Lisa D. Levine, Michal A. Elovitz, and Olga C. Irizarry.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.